ADC Therapeutics SA Key Executives

This section highlights ADC Therapeutics SA's key executives, including their titles and compensation details.

Unlock Executive Information

Upgrade to access executive details

Upgrade Now

Find Contacts at ADC Therapeutics SA

(Showing 0 of )

Unlock Team Information

Upgrade to access team member details

Upgrade Now

ADC Therapeutics SA Earnings

This section highlights ADC Therapeutics SA's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: May 05, 2025
Time: Before Market
Est. EPS: $-0.38
Status: Unconfirmed

Last Earnings Results

Date: March 27, 2025
EPS: $-0.29
Est. EPS: $-0.35
Revenue: $16.91M

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-03-27 $-0.35 $-0.29
Read Transcript Q3 2024 2024-11-09 N/A N/A
Read Transcript Q2 2024 2024-08-11 N/A N/A
Read Transcript Q1 2024 2024-05-06 $-0.56 $-0.56
Read Transcript Q4 2023 2024-03-13 $-0.47 $-1.03
Read Transcript Q3 2023 2023-11-07 $-0.61 $-0.58
Read Transcript Q2 2023 2023-08-08 $-0.44 $-0.58
Read Transcript Q1 2023 2023-05-09 $-0.80 $-0.74

Financial Statements

Access annual & quarterly financial statements for ADC Therapeutics SA, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Revenue $69.28M $69.56M $209.91M $33.92M $-
Cost of Revenue $5.95M $2.53M $4.58M $1.39M $1.97M
Gross Profit $63.33M $67.03M $205.33M $32.52M $-1.97M
Gross Profit Ratio 91.41% 96.36% 97.82% 95.89% -
Research and Development Expenses $109.63M $127.13M $187.90M $158.00M $142.03M
General and Administrative Expenses $64.47M $48.42M $141.06M $71.46M $77.23M
Selling and Marketing Expenses $21.44M $57.46M $69.05M $64.78M $22.10M
Selling General and Administrative Expenses $85.91M $105.89M $141.06M $136.24M $77.23M
Other Expenses $- $- $14.58M $28.49M $-46.40M
Operating Expenses $192.27M $233.01M $328.96M $294.24M $219.26M
Cost and Expenses $201.49M $235.54M $333.54M $295.64M $219.26M
Interest Income $12.27M $10.54M $17.97M $66.00K $832.00K
Interest Expense $50.21M $46.33M $36.92M $18.34M $4.93M
Depreciation and Amortization $3.28M $3.27M $2.39M $2.63M $1.97M
EBITDA $-103.71M $-146.76M $-108.06M $-223.72M $-219.26M
EBITDA Ratio -149.70% -210.99% -51.48% -659.60% -
Operating Income $-130.65M $-165.99M $-123.63M $-261.72M $-219.26M
Operating Income Ratio -188.59% -238.63% -58.90% -771.65% -
Total Other Income Expenses Net $-25.48M $-29.43M $-33.56M $10.21M $-26.70M
Income Before Tax $-156.14M $-195.42M $-154.66M $-251.50M $-245.96M
Income Before Tax Ratio -225.37% -280.94% -73.68% -741.53% -
Income Tax Expense $166.00K $39.11M $1.14M $-21.48M $327.00K
Net Income $-157.85M $-240.05M $-155.80M $-230.03M $-246.29M
Net Income Ratio -227.84% -345.11% -74.22% -678.20% -
EPS $-1.62 $-2.94 $-1.99 $-3.00 $-3.77
EPS Diluted $-1.62 $-2.94 $-1.99 $-3.00 $-3.77
Weighted Average Shares Outstanding 97.16M 81.71M 78.15M 76.75M 65.41M
Weighted Average Shares Outstanding Diluted 97.16M 81.71M 78.15M 76.75M 65.41M
SEC Filing Source Source Source Source Source


Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Revenue $16.91M $18.46M $17.41M $18.05M $16.79M $14.49M $19.28M $18.99M $69.80M $76.32M $17.29M $46.50M $17.01M $13.15M $3.76M $- $51.90M $- $- $-
Cost of Revenue $1.37M $851.00K $2.06M $3.35M $1.22M $366.00K $1.32M $590.00K $489.00K $1.29M $2.27M $529.00K $770.00K $502.00K $121.00K $578.00K $25.95M $32.16M $25.95M $35.38M
Gross Profit $15.54M $17.61M $15.36M $14.70M $15.57M $14.13M $17.96M $18.40M $69.31M $75.03M $15.03M $45.97M $16.24M $12.64M $3.64M $-578.00K $25.95M $-32.16M $-25.95M $-35.38M
Gross Profit Ratio 91.89% 95.39% 88.20% 81.43% 92.76% 97.47% 93.16% 96.89% 99.30% 98.30% 86.89% 98.86% 95.47% 96.18% 96.78% - 50.00% - - -
Research and Development Expenses $27.10M $32.50M $24.30M $25.73M $30.33M $28.44M $31.94M $39.48M $48.73M $41.68M $48.54M $48.95M $42.49M $36.80M $39.53M $39.17M $48.55M $32.16M $25.95M $35.38M
General and Administrative Expenses $15.15M $15.62M $16.09M $17.61M $17.21M $15.06M $12.60M $15.14M $15.14M $36.46M $35.90M $19.01M $17.93M $33.63M $19.37M $17.58M $20.10M $20.27M $19.00M $5.88M
Selling and Marketing Expenses $5.72M $5.06M $4.85M $5.81M $9.28M $8.04M $8.33M $15.35M $16.18M $8.24M $9.26M $18.37M $18.60M $17.05M $15.22M $13.91M $9.35M $6.12M $4.00M $2.63M
Selling General and Administrative Expenses $20.87M $20.68M $20.10M $22.58M $25.22M $23.09M $12.60M $30.49M $31.31M $36.46M $35.90M $37.38M $36.53M $33.63M $34.59M $31.49M $29.45M $20.27M $19.00M $8.51M
Other Expenses $- $- $2.23M $263.00K $3.78M $683.00K $296.00K $1.41M $-1.27M $11.84M $114.00K $8.00K $15.93M $-7.15M $2.10M $21.36M $143.00K $34.01M $-80.70M $148.00K
Operating Expenses $47.98M $53.18M $44.40M $48.31M $55.55M $51.53M $57.75M $69.97M $80.05M $78.14M $84.44M $86.33M $79.02M $70.44M $74.12M $70.67M $78.00M $52.43M $44.95M $43.88M
Cost and Expenses $49.35M $54.03M $46.45M $51.67M $56.77M $51.90M $59.07M $70.56M $80.54M $79.44M $86.70M $86.86M $79.79M $70.94M $74.24M $70.67M $78.00M $52.43M $44.95M $43.88M
Interest Income $2.63M $3.44M $3.25M $2.95M $3.29M $3.14M $2.37M $2.30M $1.63M $273.00K $16.00K $18.31M $20.00K $16.00K $15.00K $15.00K $100.00K $163.00K $195.00K $374.00K
Interest Expense $11.92M $13.12M $12.68M $12.50M $12.91M $12.94M $15.86M $10.42M $9.80M $11.36M $8.80M $9.22M $9.52M $4.26M $2.56M $2.00M $2.05M $1.94M $897.00K $42.00K
Depreciation and Amortization $793.00K $802.00K $838.00K $843.00K $1.01M $793.00K $769.00K $694.00K $802.00K $572.00K $586.00K $594.00K $759.00K $658.00K $635.00K $578.00K $819.00K $489.00K $437.00K $443.00K
EBITDA $-18.57M $-29.70M $-22.52M $-32.66M $-26.96M $-32.99M $-37.12M $-47.35M $-8.30M $-37.38M $-54.13M $-5.52M $-43.31M $-64.27M $-69.14M $-48.31M $-52.94M $-17.90M $-125.56M $-43.33M
EBITDA Ratio -109.79% -160.85% -129.33% -180.93% -160.59% -227.65% -192.50% -249.34% -11.90% -48.98% -313.06% -11.87% -254.60% -488.86% -1838.80% - -102.00% - - -
Operating Income $-32.44M $-35.56M $-29.04M $-33.61M $-39.98M $-37.40M $-39.79M $-51.57M $-10.74M $6.87M $-69.41M $-40.36M $-62.78M $-57.79M $-70.48M $-70.67M $-78.00M $-52.43M $-44.95M $-43.88M
Operating Income Ratio -191.82% -192.61% -166.81% -186.19% -238.11% -258.08% -206.34% -271.55% -15.38% 9.00% -401.43% -86.81% -369.08% -439.58% -1874.52% - -150.29% - - -
Total Other Income Expenses Net $1.39M $-8.05M $-6.99M $-12.39M $-2.65M $-10.49M $-12.86M $-6.89M $-10.87M $-48.20M $4.09M $22.53M $6.43M $-13.61M $-1.85M $19.25M $22.20M $32.10M $-81.50M $509.00K
Income Before Tax $-31.05M $-43.62M $-36.03M $-46.00M $-39.87M $-47.89M $-53.73M $-59.69M $-20.19M $-51.32M $-65.32M $-17.83M $-56.35M $-71.40M $-72.33M $-51.42M $-55.80M $-20.33M $-126.45M $-43.38M
Income Before Tax Ratio -183.61% -236.24% -206.97% -254.82% -237.47% -330.46% -278.62% -314.28% -28.93% -67.24% -377.77% -38.35% -331.29% -543.12% -1923.64% - -107.52% - - -
Income Tax Expense $-321.00K $90.00K $-86.00K $-84.00K $43.17M $-86.00K $-6.61M $-262.00K $3.97M $-711.00K $-947.00K $-1.17M $-21.97M $145.00K $240.00K $107.00K $126.00K $-3.00K $104.00K $100.00K
Net Income $-30.73M $-43.97M $-36.54M $-46.61M $-85.03M $-47.81M $-47.12M $-59.43M $-24.16M $-50.61M $-64.37M $-16.66M $-34.38M $-71.55M $-72.57M $-51.53M $-55.93M $-20.33M $-126.56M $-43.48M
Net Income Ratio -181.71% -238.13% -209.90% -258.16% -506.44% -329.86% -244.34% -312.90% -34.61% -66.31% -372.30% -35.83% -202.12% -544.22% -1930.03% - -107.76% - - -
EPS $-0.29 $-0.42 $-0.38 $-0.56 $-1.03 $-0.58 $-0.58 $-0.74 $-0.30 $-0.65 $-0.84 $-0.22 $-0.45 $-0.93 $-0.95 $-0.67 $-0.73 $-0.29 $-2.01 $-0.68
EPS Diluted $-0.29 $-0.42 $-0.38 $-0.56 $-1.03 $-0.58 $-0.58 $-0.74 $-0.30 $-0.65 $-0.84 $-0.22 $-0.45 $-0.93 $-0.95 $-0.67 $-0.73 $-0.29 $-2.01 $-0.68
Weighted Average Shares Outstanding 105.40M 104.82M 95.69M 82.55M 82.29M 82.26M 81.47M 80.81M 80.64M 78.37M 76.91M 76.82M 76.40M 76.74M 76.73M 76.72M 76.72M 70.91M 62.86M 63.93M
Weighted Average Shares Outstanding Diluted 105.40M 104.82M 95.69M 82.55M 82.29M 82.26M 81.47M 80.81M 80.64M 78.37M 76.91M 76.82M 76.40M 76.74M 76.73M 76.72M 76.72M 70.91M 62.86M 63.93M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Cash and Cash Equivalents $250.87M $278.60M $326.44M $466.54M $439.19M
Short Term Investments $- $- $- $- $-
Cash and Short Term Investments $250.87M $278.60M $326.44M $466.54M $439.19M
Net Receivables $20.32M $25.18M $72.97M $30.22M $-
Inventory $18.39M $16.18M $18.56M $11.12M $6.50M
Other Current Assets $17.82M $16.33M $23.50M $17.30M $11.26M
Total Current Assets $307.39M $336.29M $446.01M $525.18M $450.45M
Property Plant Equipment Net $13.43M $16.13M $9.98M $11.23M $4.76M
Goodwill $- $- $- $- $-
Intangible Assets $- $- $14.36M $13.58M $10.18M
Goodwill and Intangible Assets $- $- $14.36M $13.58M $10.18M
Long Term Investments $- $1.65M $31.15M $41.24M $47.91M
Tax Assets $- $- $26.76M $26.05M $-
Other Non-Current Assets $1.16M $711.00K $903.00K $693.00K $397.00K
Total Non-Current Assets $14.59M $18.49M $83.15M $92.79M $63.24M
Other Assets $- $- $- $- $-
Total Assets $321.98M $354.78M $529.17M $617.97M $513.69M
Account Payables $18.03M $15.57M $12.35M $12.08M $5.28M
Short Term Debt $- $1.47M $1.10M $8.63M $5.63M
Tax Payables $- $- $- $3.75M $149.00K
Deferred Revenue $- $- $- $3.75M $149.00K
Other Current Liabilities $62.44M $50.63M $68.49M $49.47M $29.37M
Total Current Liabilities $80.47M $67.67M $98.96M $73.94M $40.44M
Long Term Debt $121.63M $122.91M $116.28M $132.09M $37.24M
Deferred Revenue Non-Current $- $- $23.54M $23.54M $23.54M
Deferred Tax Liabilities Non-Current $- $- $- $- $76.75M
Other Non-Current Liabilities $322.53M $312.45M $838.00K $3.65M $76.97M
Total Non-Current Liabilities $444.15M $435.36M $341.48M $377.95M $137.75M
Other Liabilities $- $- $- $- $-
Total Liabilities $524.62M $503.03M $440.44M $451.88M $178.19M
Preferred Stock $- $- $- $- $-
Common Stock $8.43M $7.31M $7.31M $6.45M $6.31M
Retained Earnings $-1.49B $-1.34B $-1.08B $-924.88M $-694.86M
Accumulated Other Comprehensive Income Loss $-1.42M $-93.00K $155.33M $102.83M $43.00M
Other Total Stockholders Equity $1.28B $1.18B $1.17B $981.70M $981.05M
Total Stockholders Equity $-202.64M $-148.25M $88.73M $166.09M $335.50M
Total Equity $-202.64M $-148.25M $88.73M $166.09M $335.50M
Total Liabilities and Stockholders Equity $321.98M $354.78M $529.17M $617.97M $513.69M
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $321.98M $354.78M $529.17M $617.97M $513.69M
Total Investments $- $1.65M $31.15M $41.24M $47.91M
Total Debt $123.00M $124.38M $117.38M $101.75M $41.87M
Net Debt $-127.87M $-154.22M $-209.07M $-364.79M $-397.32M


Balance Sheet Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Cash and Cash Equivalents $250.87M $274.27M $300.12M $234.28M $278.60M $310.41M $347.51M $310.55M $326.44M $380.86M $376.78M $430.87M $466.54M $530.19M $371.88M $383.12M $439.19M $494.42M $348.59M $-115.55M
Short Term Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $231.10M
Cash and Short Term Investments $250.87M $274.27M $300.12M $234.28M $278.60M $310.41M $347.51M $310.55M $326.44M $380.86M $376.78M $430.87M $466.54M $530.19M $371.88M $383.12M $439.19M $494.42M $348.59M $115.55M
Net Receivables $20.32M $24.03M $22.87M $23.19M $25.18M $21.18M $23.87M $24.04M $72.97M $23.25M $20.86M $26.75M $30.22M $15.90M $2.08M $- $- $- $- $-
Inventory $18.39M $16.07M $15.19M $16.00M $16.18M $22.73M $19.43M $18.25M $18.56M $15.74M $14.65M $11.84M $11.12M $8.01M $7.72M $- $6.50M $- $- $-
Other Current Assets $17.82M $18.63M $17.18M $16.74M $16.33M $21.28M $22.00M $27.17M $26.16M $18.24M $12.15M $18.25M $17.30M $14.31M $12.75M $10.12M $11.26M $12.00M $10.53M $-
Total Current Assets $307.39M $333.00M $355.36M $290.21M $336.29M $375.60M $412.81M $380.01M $446.01M $438.10M $424.44M $487.71M $525.18M $568.41M $394.43M $393.24M $450.45M $506.42M $359.12M $115.55M
Property Plant Equipment Net $13.43M $14.91M $15.17M $15.84M $16.13M $15.53M $16.37M $15.71M $9.98M $9.88M $9.69M $10.66M $11.23M $11.56M $11.34M $10.54M $4.76M $4.90M $5.51M $-
Goodwill $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-178.65M $-
Intangible Assets $- $- $- $- $- $12.36M $13.54M $13.59M $14.36M $14.60M $14.57M $13.85M $13.58M $13.32M $12.01M $10.15M $10.18M $9.81M $187.48M $-
Goodwill and Intangible Assets $- $- $- $- $- $12.36M $13.54M $13.59M $14.36M $14.60M $14.57M $13.85M $13.58M $13.32M $12.01M $10.15M $10.18M $9.81M $8.82M $-
Long Term Investments $- $- $260.00K $930.00K $1.65M $26.99M $28.32M $29.53M $31.15M $34.69M $36.82M $38.73M $41.24M $44.00M $46.21M $47.38M $47.91M $- $- $-
Tax Assets $- $- $- $- $- $35.40M $34.82M $27.61M $26.76M $33.60M $34.04M $29.91M $26.05M $- $- $- $- $- $- $-
Other Non-Current Assets $1.16M $1.17M $992.00K $986.00K $711.00K $1.02M $1.44M $1.23M $903.00K $899.00K $899.00K $1.02M $693.00K $691.00K $394.00K $392.00K $397.00K $389.00K $384.00K $-115.55M
Total Non-Current Assets $14.59M $16.07M $16.42M $17.76M $18.49M $91.30M $94.49M $87.67M $83.15M $93.66M $96.02M $94.18M $92.79M $69.57M $69.95M $68.46M $63.24M $15.11M $14.72M $-115.55M
Other Assets $- $- $- $1 $1 $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $321.98M $349.08M $371.78M $307.97M $354.78M $466.90M $507.30M $467.67M $529.17M $531.76M $520.46M $581.89M $617.97M $637.98M $464.39M $461.70M $513.69M $521.53M $373.84M $-
Account Payables $18.03M $14.37M $10.71M $14.31M $15.57M $8.98M $11.69M $8.69M $12.35M $11.61M $13.02M $16.45M $12.08M $12.03M $14.63M $11.46M $5.28M $6.15M $6.80M $-
Short Term Debt $1.37M $- $1.42M $1.43M $2.93M $15.75M $15.49M $14.98M $14.67M $13.30M $7.48M $7.53M $8.63M $7.59M $7.18M $4.43M $5.63M $3.69M $4.21M $-
Tax Payables $- $- $- $- $- $- $- $- $- $- $799.00K $6.38M $3.75M $- $237.00K $237.00K $149.00K $91.00K $148.00K $-
Deferred Revenue $- $- $- $- $- $- $- $- $- $- $- $- $3.75M $- $237.00K $237.00K $149.00K $91.00K $20.36M $-
Other Current Liabilities $61.07M $53.31M $45.51M $47.24M $49.17M $53.48M $53.40M $57.41M $71.94M $62.66M $52.38M $40.41M $49.47M $39.69M $29.21M $25.27M $29.37M $22.63M $-148.00K $-
Total Current Liabilities $80.47M $67.68M $57.63M $62.98M $67.67M $78.21M $80.58M $81.09M $98.96M $87.57M $73.68M $70.77M $73.94M $59.30M $51.50M $41.40M $40.44M $32.56M $31.37M $-
Long Term Debt $121.63M $340.39M $122.98M $122.90M $122.91M $107.78M $108.12M $107.97M $103.80M $103.35M $95.83M $95.03M $132.09M $93.06M $92.26M $43.37M $37.24M $36.39M $36.19M $-
Deferred Revenue Non-Current $- $- $316.21M $310.01M $303.57M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $23.54M $- $- $-
Deferred Tax Liabilities Non-Current $- $- $9.31M $9.66M $10.18M $305.36M $299.81M $- $- $- $- $- $- $-96.98M $-93.99M $-51.02M $76.75M $- $- $-
Other Non-Current Liabilities $322.53M $112.95M $322.83M $6.52M $312.45M $6.29M $27.38M $845.00K $1.79M $4.29M $7.64M $253.42M $3.65M $298.31M $53.17M $55.43M $76.97M $76.51M $109.98M $-
Total Non-Current Liabilities $444.15M $453.35M $445.82M $439.43M $435.36M $442.88M $435.31M $348.90M $341.48M $339.40M $331.43M $348.44M $377.95M $391.37M $168.97M $122.34M $137.75M $112.90M $146.17M $-
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $524.62M $521.02M $503.45M $502.42M $503.03M $521.08M $515.89M $429.99M $440.44M $426.98M $405.12M $419.22M $451.88M $450.67M $220.47M $163.74M $178.19M $145.47M $177.54M $-
Preferred Stock $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $8.43M $8.23M $8.23M $7.31M $7.31M $7.31M $7.31M $7.31M $7.31M $6.70M $6.45M $6.45M $6.45M $6.45M $6.45M $6.31M $6.31M $6.31M $5.79M $-
Retained Earnings $-1.49B $-1.46B $-1.42B $-1.38B $-1.34B $-1.24B $-1.19B $-1.14B $-1.08B $-1.06B $-1.01B $-941.55M $-924.88M $-890.50M $-818.96M $-746.39M $-694.86M $-638.93M $-618.60M $-
Accumulated Other Comprehensive Income Loss $-1.42M $203.00K $-338.00K $-201.00K $-93.00K $166.00M $164.13M $163.29M $155.33M $147.20M $133.12M $116.07M $102.83M $89.93M $75.27M $56.98M $43.00M $27.65M $16.51M $111.16M
Other Total Stockholders Equity $1.28B $1.28B $1.28B $1.18B $1.18B $1.01B $1.01B $1.01B $1.01B $1.01B $981.70M $981.70M $981.70M $981.44M $981.16M $981.05M $981.05M $981.03M $792.60M $-
Total Stockholders Equity $-202.64M $-171.95M $-131.67M $-194.45M $-148.25M $-54.18M $-8.59M $37.69M $88.73M $104.78M $115.35M $162.67M $166.09M $187.31M $243.92M $297.97M $335.50M $376.06M $196.30M $111.16M
Total Equity $-202.64M $-171.95M $-131.67M $-194.45M $-148.25M $-54.18M $-8.59M $37.69M $88.73M $104.78M $115.35M $162.67M $166.09M $187.31M $243.92M $297.97M $335.50M $376.06M $196.30M $111.16M
Total Liabilities and Stockholders Equity $321.98M $349.08M $371.78M $307.97M $354.78M $466.90M $507.30M $467.67M $529.17M $531.76M $520.46M $581.89M $617.97M $637.98M $464.39M $461.70M $513.69M $521.53M $373.84M $111.16M
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $321.98M $349.08M $371.78M $307.97M $354.78M $466.90M $507.30M $467.67M $529.17M $531.76M $520.46M $581.89M $617.97M $637.98M $464.39M $461.70M $513.69M $521.53M $373.84M $111.16M
Total Investments $- $- $260.00K $930.00K $1.65M $26.99M $28.32M $29.53M $31.15M $34.69M $36.82M $38.73M $41.24M $44.00M $46.21M $47.38M $47.91M $- $- $231.10M
Total Debt $123.00M $331.51M $124.40M $124.33M $124.38M $123.53M $123.61M $122.95M $117.38M $116.66M $103.32M $102.56M $101.75M $100.65M $99.44M $47.80M $41.87M $40.09M $40.40M $-
Net Debt $-127.87M $57.24M $-175.72M $-109.96M $-154.22M $-186.88M $-223.90M $-187.60M $-209.07M $-264.20M $-273.46M $-328.31M $-364.79M $-429.55M $-272.44M $-335.32M $-397.32M $-454.33M $-308.19M $115.55M

Annual Cash Flow

Breakdown December 31, 2024 December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020
Net Income $-157.85M $-240.05M $-155.80M $-230.03M $-246.29M
Depreciation and Amortization $3.28M $3.27M $2.33M $2.63M $2.19M
Deferred Income Tax $- $37.10M $-708.00K $-21.48M $327.00K
Stock Based Compensation $6.57M $13.49M $49.32M $60.48M $37.59M
Change in Working Capital $- $44.27M $-33.01M $-20.28M $12.36M
Accounts Receivables $4.77M $47.79M $-42.75M $-30.22M $-
Inventory $1.52M $1.61M $-8.96M $-3.02M $-
Accounts Payables $2.46M $3.17M $310.00K $6.80M $1.92M
Other Working Capital $- $-8.30M $18.40M $6.16M $10.44M
Other Non Cash Items $24.17M $23.23M $1.07M $-24.70M $25.10M
Net Cash Provided by Operating Activities $-123.83M $-118.69M $-136.79M $-233.38M $-168.73M
Investments in Property Plant and Equipment $-867.00K $-3.22M $-2.30M $-6.38M $-2.81M
Acquisitions Net $- $- $- $- $-
Purchases of Investments $- $- $- $- $-
Sales Maturities of Investments $- $- $- $- $-
Other Investing Activities $- $- $-210.00K $-297.00K $-19.00K
Net Cash Used for Investing Activities $-867.00K $-3.22M $-2.51M $-6.67M $-2.83M
Debt Repayment $- $- $-2.71M $48.61M $61.75M
Common Stock Issued $60.51M $773.00K $6.13M $778.00K $433.16M
Common Stock Repurchased $- $- $-221.00K $- $-
Dividends Paid $- $- $- $- $-
Other Financing Activities $36.55M $73.88M $-4.32M $218.78M $54.00K
Net Cash Used Provided by Financing Activities $97.05M $73.88M $-593.00K $267.39M $494.97M
Effect of Forex Changes on Cash $-83.00K $184.00K $-208.00K $6.00K $235.00K
Net Change in Cash $-27.73M $-47.84M $-140.10M $27.35M $323.64M
Cash at End of Period $250.87M $278.60M $326.44M $466.54M $439.19M
Cash at Beginning of Period $278.60M $326.44M $466.54M $439.19M $115.55M
Operating Cash Flow $-123.83M $-118.69M $-136.79M $-233.38M $-168.73M
Capital Expenditure $-867.00K $-3.22M $-2.30M $-6.38M $-2.81M
Free Cash Flow $-124.70M $-121.90M $-139.09M $-239.75M $-171.54M

Cash Flow Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Net Income $-30.73M $-43.97M $-36.54M $-46.61M $-85.70M $-47.81M $-47.12M $-59.43M $-24.16M $-50.61M $-64.37M $-16.66M $-34.38M $-71.55M $-72.57M $-51.53M $-55.93M $-20.33M $-126.56M $-43.48M
Depreciation and Amortization $793.00K $802.00K $838.00K $843.00K $1.01M $793.00K $769.00K $694.00K $576.00K $572.00K $586.00K $594.00K $759.00K $658.00K $635.00K $578.00K $819.00K $489.00K $437.00K $443.00K
Deferred Income Tax $- $- $- $- $45.75M $-578.00K $-7.22M $-848.00K $6.84M $441.00K $-4.13M $-3.86M $-21.97M $145.00K $240.00K $107.00K $126.00K $-3.00K $104.00K $100.00K
Stock Based Compensation $1.62M $2.81M $1.99M $158.00K $1.55M $2.51M $1.36M $8.07M $7.54M $14.56M $13.82M $13.40M $13.46M $14.80M $18.27M $13.95M $15.42M $10.99M $7.39M $3.79M
Change in Working Capital $10.03M $8.54M $-4.58M $-9.92M $10.18M $224.00K $251.00K $33.62M $-43.28M $-4.65M $16.47M $-1.55M $-9.58M $-13.85M $1.49M $1.66M $9.90M $-2.22M $-2.27M $6.95M
Accounts Receivables $3.71M $-1.22M $281.05K $2.00M $-4.00M $2.70M $188.00K $48.90M $-49.69M $-2.42M $5.89M $3.47M $-14.32M $-13.82M $-2.08M $- $- $- $1.00K $-1.00K
Inventory $-2.80M $1.09M $518.82K $-568.00K $-332.00K $-3.30M $-1.90M $-175.00K $-2.82M $-1.86M $-3.93M $-355.00K $-2.06M $7.00K $-966.00K $- $- $- $- $-
Accounts Payables $3.68M $4.77M $-4.74M $-1.25M $6.57M $-836.00K $1.10M $-3.66M $721.00K $-1.38M $-3.41M $4.38M $1.74M $-3.93M $3.07M $5.91M $-277.00K $-1.27M $-1.81M $5.28M
Other Working Capital $5.43M $3.91M $-640.87K $-10.10M $7.94M $1.66M $866.00K $-11.45M $8.51M $1.01M $17.93M $-9.04M $5.06M $3.89M $499.00K $-4.26M $10.18M $-947.00K $-460.00K $1.67M
Other Non Cash Items $-3.56M $6.78M $14.31M $13.10M $-5.86M $10.84M $15.37M $2.88M $383.00K $41.88M $-15.38M $-25.81M $-9.92M $11.21M $-6.07M $-19.91M $-22.02M $-33.28M $80.31M $88.00K
Net Cash Provided by Operating Activities $-21.85M $-25.04M $-31.58M $-44.09M $-33.07M $-34.02M $-36.83M $-14.77M $-52.10M $2.19M $-53.01M $-33.88M $-61.63M $-58.59M $-58.01M $-55.15M $-51.69M $-44.35M $-40.59M $-32.10M
Investments in Property Plant and Equipment $-90.00K $-216.00K $-20.80K $-531.00K $-327.00K $-661.00K $-1.21M $-1.02M $-117.00K $-254.00K $-809.00K $-1.12M $-533.00K $-2.34M $-2.85M $-657.00K $-774.00K $-1.40M $-158.00K $-476.00K
Acquisitions Net $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Purchases of Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Sales Maturities of Investments $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Investing Activities $- $- $- $- $-200.00K $2.01K $200.00K $-20.00K $-1.95K $-595 $120.00K $-330.00K $-297.00K $-933.00K $-1.90M $- $-19.00K $-1.00M $20.00K $-20.00K
Net Cash Used for Investing Activities $-90.00K $-216.00K $-20.80K $-531.00K $-527.00K $-661.00K $-1.01M $-1.02M $-117.00K $-254.00K $-689.00K $-1.45M $-830.00K $-2.34M $-2.85M $-657.00K $-793.00K $-1.40M $-138.00K $-496.00K
Debt Repayment $- $- $- $- $- $-409.00K $- $- $-1.93M $114.24M $- $-258.00K $-231.00K $-229.00K $49.37M $-300.00K $-215.00K $-373.00K $62.62M $-278.00K
Common Stock Issued $- $-1.23M $97.07M $356.00K $782.96K $- $- $- $- $6.08M $- $- $260.58K $277.55K $230.44K $3.00K $-2.71M $191.66M $- $-
Common Stock Repurchased $- $- $- $- $- $- $- $- $-218.94K $- $- $- $- $- $- $- $- $- $- $-
Dividends Paid $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Other Financing Activities $-1.12M $346.00K $98.70M $356.00K $1.64M $-1.21M $73.10M $425.00K $-238.55K $-111.88M $-252.00K $- $-987.00K $219.53M $231.00K $3.00K $54.00K $- $244.15M $-
Net Cash Used Provided by Financing Activities $-1.12M $-879.00K $97.07M $356.00K $1.64M $-2.31M $74.74M $-196.00K $-2.45M $2.37M $-252.00K $-258.00K $-1.22M $219.30M $49.60M $-297.00K $-2.87M $191.34M $306.77M $-278.00K
Effect of Forex Changes on Cash $-343.00K $291.00K $12.00K $-43.00K $152.00K $-118.00K $61.00K $89.00K $243.00K $-224.00K $-145.00K $-82.00K $29.00K $-68.00K $15.00K $30.00K $137.00K $228.00K $-30.00K $-100.00K
Net Change in Cash $-23.41M $-25.85M $65.83M $-44.31M $-31.81M $-37.10M $36.96M $-15.89M $-54.42M $4.08M $-54.10M $-35.67M $-63.65M $158.31M $-11.24M $-56.07M $-55.22M $145.82M $266.02M $-32.98M
Cash at End of Period $250.87M $274.27M $300.12M $234.28M $278.60M $310.41M $347.51M $310.55M $326.44M $380.86M $376.78M $430.87M $466.54M $530.19M $371.88M $383.12M $439.19M $494.42M $348.59M $82.58M
Cash at Beginning of Period $274.27M $300.12M $234.28M $278.60M $310.41M $347.51M $310.55M $326.44M $380.86M $376.78M $430.87M $466.54M $530.19M $371.88M $383.12M $439.19M $494.42M $348.59M $82.58M $115.55M
Operating Cash Flow $-21.85M $-25.04M $-31.58M $-44.09M $-33.07M $-34.02M $-36.83M $-14.77M $-52.10M $2.19M $-53.01M $-33.88M $-61.63M $-58.59M $-58.01M $-55.15M $-51.69M $-44.35M $-40.59M $-32.10M
Capital Expenditure $-90.00K $-216.00K $-20.80K $-531.00K $-327.00K $-661.00K $-1.21M $-1.02M $-117.00K $-254.00K $-809.00K $-1.12M $-533.00K $-2.34M $-2.85M $-657.00K $-774.00K $-1.40M $-158.00K $-476.00K
Free Cash Flow $-21.94M $-25.26M $-31.60M $-44.63M $-33.40M $-34.68M $-38.04M $-15.79M $-52.21M $1.94M $-53.82M $-35.00M $-62.16M $-60.93M $-60.86M $-55.81M $-52.47M $-45.75M $-40.74M $-32.58M

ADC Therapeutics SA (ADCT)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Healthcare Biotechnology

$1.48

Stock Price

$146.29M

Market Cap

263

Employees

Epalinges, None

Location

Revenue (FY 2024)

$69.28M

-0.4% YoY

Net Income (FY 2024)

$-157.85M

34.2% YoY

EPS (FY 2024)

$-1.62

44.9% YoY

Free Cash Flow (FY 2024)

$-124.70M

-2.3% YoY

Profitability

Gross Margin

91.4%

Net Margin

-227.8%

ROE

77.9%

ROA

-49.0%

Valuation

P/E Ratio

-1.22

P/S Ratio

2.79

EV/EBITDA

-0.63

Market Cap

$146.29M

Revenue & Net Income

Profit Margins

Cash Flow Summary

Operating Cash Flow

$-123.83M

-4.3% YoY

Free Cash Flow

$-124.70M

-2.3% YoY

Balance Sheet Summary

Total Assets

$321.98M

-9.2% YoY

Total Debt

$123.00M

1.1% YoY

Shareholder Equity

$-202.64M

-15.0% YoY

Dividend Overview

No Dividend Data

ADC Therapeutics SA doesn't currently pay dividends.

ADC Therapeutics SA Dividends

Explore ADC Therapeutics SA's dividend history, including dividend yield, payout ratio, and historical payments.

ADC Therapeutics SA does not currently pay a dividend.

ADC Therapeutics SA News

Read the latest news about ADC Therapeutics SA, including recent articles, headlines, and updates.

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News image

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian and non-small lung cancer Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-targeted ADCs LAUSANNE, Switzerland , April 28, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based antibody drug conjugates (ADCs) targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ACST2) as presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. "We believe these presentations demonstrate the strong potential of our exatecan-based ADCs to treat a wide range of solid and hematologic cancers beyond lymphoma.

News image

Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer Treatment

The global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of incremental progress, new therapies like antibody-drug conjugates (ADCs) and immunotherapies are making strides against some of oncology's toughest challenges: rare pediatric cancers, relapsed tumors, and diseases like osteosarcoma, where survival rates have barely improved in decades. Regulators are helping accelerate this progress with tools like accelerated approvals and breakthrough designations that are shortening development timelines. At the same time, approaches like comparative oncology-using naturally occurring canine cancers as research models-are providing faster, more clinically relevant data than traditional preclinical studies. This convergence of scientific advancement and commercial opportunity is creating a market that's evolving faster than ever before. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); Within this expanding landscape, several companies are at the forefront of pioneering new treatments. Let's take a closer look at how some of the most innovative players in this space are tackling these pressing challenges.OS Therapies (NYSE-A: OSTX) is focused on transforming the treatment landscape for osteosarcoma, a rare and aggressive bone cancer that primarily affects children and young adults. The company's lead drug, OST-HER2, is a novel off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to stimulate the immune system to target and destroy cancer cells that express the HER2 protein. Recent data has further validated the potential of OST-HER2 in treating osteosarcoma. New unpublished research shows that when combined with palliative radiation, OST-HER2 has had a significant impact on dogs with unresected, primary osteosarcoma. Out of 15 dogs treated, 5 experienced survival times exceeding 500 days, with clinical and radiographic arrest of the primary tumor and delayed pulmonary metastases. These findings could have profound implications for the potential use of OST-HER2 as a frontline therapy in humans, potentially before chemotherapy is even considered. This approach could reduce or even eliminate the need for surgery and chemotherapy, offering a more effective and less invasive treatment alternative for patients. This data complements previous research published in the journal Molecular Therapy, which demonstrated how OST-HER2 induces strong immune responses from the very first dose. These responses were shown to correlate with both the prevention of metastasis and long-term survival in dogs that had undergone surgery to remove their primary osteosarcoma. Additionally, the study showed that dogs who initially had weaker immune responses showed significant improvement after the second and third doses, supporting the use of repeated dosing as a potential strategy for treating the disease. The combination of these results marks a critical milestone in OS Therapies' development of OST-HER2. The company is now preparing to submit this new data to the USDA, along with information on their improved manufacturing process, aiming for conditional approval in the United States by 2025. Following this, OS Therapies plans to conduct a pivotal clinical study with the goal of gaining full approval for the treatment by 2026. The company is also on track to secure FDA Accelerated Approval for OST-HER2 in human osteosarcoma, with plans to submit an application by the end of 2025. If approved, OST-HER2 could be one of the first treatments to offer a meaningful improvement in survival for patients with this rare and difficult-to-treat cancer. Moreover, a successful approval would make OS Therapies eligible for a Priority Review Voucher (PRV), which could be sold for a significant financial gain, providing the company with the resources needed to fund future projects. As OS Therapies continues to advance in both human and veterinary applications, its approach to Comparative Oncology is proving to be a game-changer. With a 96% genetic similarity between human and canine osteosarcoma, research in dogs with osteosarcoma offers valuable insights that could accelerate the development of new therapies for humans. OS Therapies is leveraging this unique advantage to not only improve treatments for dogs but also to push the boundaries of cancer treatment in humans. Financially, OS Therapies remains well-positioned for the future. The company raised $12 million in 2024 through an IPO and private placement, and it expects its cash reserves to last through mid-2026. With clinical costs now tapering off as the company moves forward in its regulatory journey, OS Therapies is in a solid position to continue advancing its pipeline without needing to raise additional capital in the near term. The company's growth isn't limited to just one drug. Beyond OST-HER2, OS Therapies is also working on an innovative antibody-drug conjugate (ADC) platform, which could allow for custom-designed cancer treatments tailored to various cancers. This growing pipeline positions OS Therapies as a company to watch in the biotech space, offering not only a potential breakthrough in osteosarcoma treatment but also future opportunities in oncology. As the company works toward Accelerated Approval for OST-HER2 by the end of 2025, the potential for significant regulatory milestones, a potential PRV sale, and an expanding clinical pipeline make OS Therapies a standout in the emerging biotech field. Investors, clinicians, and patients alike should keep a close eye on this company as it continues to push forward in the fight against osteosarcoma and other forms of cancer.Day One Biopharmaceuticals (Nasdaq: DAWN) is gaining traction in the pediatric oncology world with OJEMDA (tovorafenib), its lead treatment for children with low-grade glioma (pLGG), a rare brain cancer. OJEMDA is a Type II RAF kinase inhibitor that targets BRAF alterations, which are often found in pLGG patients. It received FDA approval under the accelerated approval pathway, and the early numbers suggest strong adoption-more than 1,600 prescriptions were written in the eight months following its April 2024 launch. Full-year net product revenue came in at $57.2 million, with $29 million in the fourth quarter alone. In late 2024, OJEMDA also earned the "Exclusively Pediatric" designation from CMS, lowering its Medicaid and 340B rebate obligations, which could help margins moving forward. The drug is currently at the center of Day One's pipeline, with the Phase 3 FIREFLY-2 study ongoing. The company expects to complete enrollment by mid-2026. Beyond OJEMDA, Day One is working to expand its reach in pediatric cancer. DAY301, an antibody-drug conjugate (ADC) targeting PTK7, has cleared its first dosing cohort in a Phase 1a/b trial. If development goes well, it could become a valuable second asset alongside OJEMDA. From a financial standpoint, Day One ended 2024 with $531.7 million in cash and equivalents, giving the company plenty of runway. While the full-year net loss totaled $95.5 million-largely due to R&D and launch costs-the company continues to invest in growth. R&D expenses jumped to $227.7 million in 2024, up from $130.5 million in 2023, driven by the advancement of DAY301 and other pipeline efforts. Even with the losses, Day One is in a strong position: OJEMDA is gaining traction, the pipeline is moving, and the balance sheet is healthy. For anyone watching the space, Day One stands out as a biotech laser-focused on filling a serious treatment gap in pediatric cancer.GSK plc (NYSE: GSK) is making real moves in oncology, especially in tough-to-treat cancers like osteosarcoma. In January, the FDA gave Breakthrough Therapy Designation to one of GSK's experimental antibody-drug conjugates (ADCs) that targets B7-H3-a protein linked to tumor growth. The drug showed early promise in a mid-stage trial for patients with relapsed or refractory osteosarcoma who've already gone through two lines of treatment. That's a big deal in a space with no currently approved therapies for patients at that stage. Osteosarcoma mostly affects children and young adults, and once it comes back after initial treatment, the outlook gets bleak. GSK's drug could help fill that gap. The company is now running a global trial aimed at eventually getting the treatment approved more broadly. On the business side, GSK is firing on all cylinders. In February the company launched a $2.5 billion stock buyback after a strong Q4 and raised its long-term revenue forecast. Oncology is now a major focus for GSK's pipeline, along with respiratory diseases, HIV, and other specialty areas. With five product approvals expected this year-including a relaunch of its blood cancer drug Blenrep-the company looks well-positioned to keep growing in high-need treatment areas.ADC Therapeutics (NYSE: ADCT) stands out as a promising player in the antibody drug conjugate (ADC) space, focusing on the treatment of hematologic malignancies and solid tumors. With a proprietary ADC technology platform, the company is positioning itself to make a significant impact in oncology. Investors looking for growth potential in this innovative field should take note of ADC Therapeutics, particularly with its lead product, ZYNLONTA (loncastuximab tesirine). Recent clinical trial results further solidify the company's growth trajectory. In December 2024, ADC Therapeutics published updated data from a Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab for treating relapsed or refractory follicular lymphoma (FL). The results showed a robust 97.4% overall response rate and 76.9% complete response rate, positioning ZYNLONTA as a strong treatment option for high-risk FL patients. These results were published in The Lancet Haematology and presented at the prestigious American Society of Hematology (ASH) Annual Meeting, raising the company's profile in the oncology field. With progression-free survival remaining strong at 94.6% at 12 months, the long-term potential for ZYNLONTA in treating indolent B-cell lymphomas is clear. Additionally, ADC Therapeutics is making strides with the LOTIS-7 trial, which is evaluating ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The initial data showed impressive results, with a 94% overall response rate and 72% complete response rate, alongside a manageable safety profile. This combination therapy could provide a competitive edge in the highly saturated DLBCL market, demonstrating the potential for ZYNLONTA beyond its initial indication. From a financial perspective, ADC Therapeutics reported stable revenues in Q4 2024, generating $16.4 million in product sales. Despite the flat revenue growth, the company is focused on reducing operating expenses, achieving a 13% year-over-year reduction. With $251 million in cash reserves at the end of 2024, the company is well-positioned to fund operations into the second half of 2026, allowing for continued investment in its clinical pipeline and commercial efforts. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by O S Therapies Inc to assist in the production and distribution of content related to OSTX. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Media Contact Company Name: RazorPitch Contact Person: Mark McKelvie Email: markrmckelvie@gmail.com City: NAPLES State: Florida Country: United States Website: https://razorpitch.com/ Source: www.abnewswire.com .(C) 2025 M2 COMMUNICATIONS, source M2 PressWIRE

News image

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.

News image

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

LAUSANNE, Switzerland , April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.

News image

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Marcy Graham - Investor Relations Officer Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Kelly Shi - Jefferies Michael Schmidt - Guggenheim Sudan Loganathan - Stephens Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all lines are in listen-only mode.

News image

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago.

News image

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 confirmatory trial of ZYNLONTA plus rituximab in patients with 2L+ DLBCL; data update anticipated in late 2025 once PFS events reached $250.9M in cash as of December 31, 2024, provides runway expected to fund operations into the second half of 2026 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland , March 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.

News image

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANNE, Switzerland , March 25, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. "We are excited to present preclinical data on our exatecan-based Claudin-6, PSMA, and ACST2-targeting antibody-drug conjugates," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics.

News image

ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million in cash but faces a net loss, with a cash runway of approximately two years. The company's near-term success hinges on the results of the LOTIS-5 trial, crucial for confirming Zynlonta's efficacy and potential market expansion.

News image

ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025

LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, March 27, 2025, at 8:30 a.m. EDT to report financial results for the fourth quarter and year ended December 31, 2024, and provide operational updates.

News image

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

LAUSANNE, Switzerland , Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Thursday, February 6, 2025, at 2:00 p.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website.

News image

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021.

News image

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034.

News image

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

News image

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma  shows ORR of 91% and 70% CR LAUSANNE, Switzerland , Dec. 9, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology (ASH) Annual Meeting and Exposition. "We are excited by the publication of these results in The Lancet Haematology demonstrating ZYNLONTA's robust clinical activity in follicular lymphoma, particularly in patients classified as high-risk POD24 and those with high tumor burden where there remains significant unmet need," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.

News image

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland , Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).

News image

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.

News image

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here's Why

News image

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.

News image

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.

News image

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 7-10, 2024. "Data from the abstract on the Phase 2 study of ZYNLONTA combined with rituximab in patients with high-risk relapsed or refractory follicular lymphoma demonstrated a robust response among the 35 evaluable patients, with an overall response rate at week 12 of 97.1%," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.

News image

ADC Therapeutics to Present at November Investor Conferences

LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024 Presentation Time: 11:00 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024 Presentation Time: 11:00 a.m.

News image

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

News image

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

LAUSANNE, Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates.

News image

Similar Companies

A
Aadi Bioscience, Inc.

AADI

Price: $2.05

Market Cap: $94.89M

A
Akero Therapeutics, Inc.

AKRO

Price: $44.92

Market Cap: $3.58B

A
Alector, Inc.

ALEC

Price: $1.16

Market Cap: $115.49M

A
AlloVir, Inc.

ALVR

Price: $9.81

Market Cap: $49.48M

A
ALX Oncology Holdings Inc.

ALXO

Price: $0.53

Market Cap: $28.44M

A
Arvinas, Inc.

ARVN

Price: $6.97

Market Cap: $479.34M

B
Black Diamond Therapeutics, Inc.

BDTX

Price: $1.68

Market Cap: $94.93M

C
Crinetics Pharmaceuticals, Inc.

CRNX

Price: $33.29

Market Cap: $3.12B

D
Design Therapeutics, Inc.

DSGN

Price: $4.46

Market Cap: $252.90M

F
Homology Medicines, Inc.

FIXX

Price: $0.93

Market Cap: $3.02M

G
Generation Bio Co.

GBIO

Price: $0.43

Market Cap: $28.82M

H
Harpoon Therapeutics, Inc.

HARP

Price: $23.01

Market Cap: $865.08M

I
Century Therapeutics, Inc.

IPSC

Price: $0.54

Market Cap: $46.90M

K
Kura Oncology, Inc.

KURA

Price: $6.50

Market Cap: $524.65M

P
Passage Bio, Inc.

PASG

Price: $0.33

Market Cap: $20.38M

P
Protagonist Therapeutics, Inc.

PTGX

Price: $44.95

Market Cap: $2.76B

R
Ultragenyx Pharmaceutical Inc.

RARE

Price: $38.48

Market Cap: $3.61B

R
Avidity Biosciences, Inc.

RNA

Price: $32.20

Market Cap: $3.87B

R
Revolution Medicines, Inc.

RVMD

Price: $40.14

Market Cap: $7.46B

S
Stoke Therapeutics, Inc.

STOK

Price: $9.70

Market Cap: $524.55M

T
TCR2 Therapeutics Inc.

TCRR

Price: $1.48

Market Cap: $58.11M

Related Metrics

Explore detailed financial metrics and analysis for ADCT.